Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment.

Ghiti Moghadam M, Lamers-Karnebeek FBG, Vonkeman HE, Ten Klooster PM, Tekstra J, van Schaeybroeck B, Klaasen R, van Onna M, Bernelot Moens HJ, Visser H, Schilder AM, Kok MR, Landewé RBM, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

BMC Rheumatol. 2019 Jun 13;3:3. doi: 10.1186/s41927-019-0071-x. eCollection 2019.

2.

Comparison of disease activity measures in early psoriatic arthritis in usual care.

Wervers K, Luime JJ, Tchetverikov I, Gerards AH, Kok MR, Appels CWY, van der Graaff WL, van Groenendael JHLM, Korswagen LA, Veris-van Dieren JJ, Hazes JMW, Vis M.

Rheumatology (Oxford). 2019 Jun 18. pii: kez215. doi: 10.1093/rheumatology/kez215. [Epub ahead of print]

PMID:
31211399
3.

Remarkable international variability in reasons for ineligibility and non-participation in the GLORIA trial.

Hartman L, Bos R, Buttgereit F, Güler-Yuksel M, Ionescu R, Kok MR, Lems WF, Micaelo M, Opris-Belinski D, Pusztai A, Santos E, Da Silva J, Szekanecz Z, Zeiner K, Zhang D, Boers M.

Scand J Rheumatol. 2019 May 27:1-2. doi: 10.1080/03009742.2018.1559880. [Epub ahead of print] No abstract available.

PMID:
31132016
4.

Semaphorin4A coordinately induces inflammation and fibrosis in systemic sclerosis.

Carvalheiro T, Affandi AJ, Malvar-Fernández B, Dullemond I, Cossu M, Ottria A, Mertens JS, Giovannone B, Bonte-Mineur F, Kok MR, Marut W, Reedquist KA, Radstake TR, García S.

Arthritis Rheumatol. 2019 Apr 23. doi: 10.1002/art.40915. [Epub ahead of print]

PMID:
31012544
5.

Incorporating geography into a new generalized theoretical and statistical framework addressing the modifiable areal unit problem.

Tuson M, Yap M, Kok MR, Murray K, Turlach B, Whyatt D.

Int J Health Geogr. 2019 Mar 27;18(1):6. doi: 10.1186/s12942-019-0170-3.

6.

Time to minimal disease activity in relation to quality of life, productivity, and radiographic damage 1 year after diagnosis in psoriatic arthritis.

Wervers K, Luime JJ, Tchetverikov I, Gerards AH, Kok MR, Appels CWY, van der Graaff WL, van Groenendael JHLM, Korswagen LA, Veris-van Dieren JJ, Hazes JMW, Vis M; Cicero.

Arthritis Res Ther. 2019 Jan 16;21(1):25. doi: 10.1186/s13075-019-1811-4.

7.

Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial.

Janssen CA, Oude Voshaar MAH, Vonkeman HE, Jansen TLTA, Janssen M, Kok MR, Radovits B, van Durme C, Baan H, van de Laar MAFJ.

Rheumatology (Oxford). 2019 Jan 2. doi: 10.1093/rheumatology/key402. [Epub ahead of print]

PMID:
30602035
8.

Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab - The GO-EASY Study.

van Bentum RE, Heslinga SC, Nurmohamed MT, Gerards AH, Griep EN, Koehorst CBJM, Kok MR, Schilder AM, Verhoef M, van der Horst-Bruinsma IE.

J Rheumatol. 2019 Feb;46(2):153-159. doi: 10.3899/jrheum.180312. Epub 2018 Nov 1.

9.

Influence of Disease Manifestations on Health-related Quality of Life in Early Psoriatic Arthritis.

Wervers K, Luime JJ, Tchetverikov I, Gerards AH, Kok MR, Appels CWY, van der Graaff WL, van Groenendael JHLM, Korswagen LA, Veris-van Dieren JJ, Hazes JMW, Vis M.

J Rheumatol. 2018 Nov;45(11):1526-1531. doi: 10.3899/jrheum.171406. Epub 2018 Jul 1.

PMID:
29961685
10.

Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis.

Wervers K, Vis M, Tchetveriko I, Gerards AH, Kok MR, Appels CWY, van der Graaff WL, van Groenendael JHLM, Korswagen LA, Veris-van Dieren JJ, Hazes JMW, Luime JJ.

Arthritis Care Res (Hoboken). 2018 Dec;70(12):1764-1770. doi: 10.1002/acr.23571.

11.

Modification of a sonographic enthesitis score to differentiate between psoriatic arthritis and young healthy volunteers.

Wervers K, Vis M, Rasappu N, van der Ven M, Tchetverikov I, Kok MR, Gerards AH, Hazes J, Luime JJ.

Scand J Rheumatol. 2018 Jul;47(4):291-294. doi: 10.1080/03009742.2017.1393695. Epub 2018 Jan 2.

PMID:
29291671
12.
13.

Efficacy of Hydroxychloroquine in Hand Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial.

Lee W, Ruijgrok L, Boxma-de Klerk B, Kok MR, Kloppenburg M, Gerards A, Huisman M, Hazes M, de Sonnaville P, Grillet B, Weel A, Basoski N.

Arthritis Care Res (Hoboken). 2018 Sep;70(9):1320-1325. doi: 10.1002/acr.23471. Epub 2018 Aug 12.

PMID:
29125901
14.

Absence of ultrasound inflammation in patients presenting with arthralgia rules out the development of arthritis.

van der Ven M, van der Veer-Meerkerk M, Ten Cate DF, Rasappu N, Kok MR, Csakvari D, Hazes JMW, Gerards AH, Luime JJ.

Arthritis Res Ther. 2017 Sep 15;19(1):202. doi: 10.1186/s13075-017-1405-y.

15.

Taking advances from bench to bedside during the last decade.

Kok MR, Tak PP.

Best Pract Res Clin Rheumatol. 2012 Apr;26(2):225-36. doi: 10.1016/j.berh.2012.03.003. Review.

PMID:
22794095
16.

Remission of incapacitating acute cutaneous lupus erythematosus in a patient with systemic lupus erythematosus by B cell-depletive therapy.

Kok MR, Vos K, Bos JD, Tak PP.

J Clin Rheumatol. 2010 Oct;16(7):345. doi: 10.1097/RHU.0b013e3181f4e4b7. No abstract available.

PMID:
20859218
17.

Local expression of tumor necrosis factor-receptor 1:immunoglobulin G can induce salivary gland dysfunction in a murine model of Sjögren's syndrome.

Vosters JL, Yin H, Roescher N, Kok MR, Tak PP, Chiorini JA.

Arthritis Res Ther. 2009;11(6):R189. doi: 10.1186/ar2888. Epub 2009 Dec 14.

18.

Re-engineering primary epithelial cells from rhesus monkey parotid glands for use in developing an artificial salivary gland.

Tran SD, Sugito T, Dipasquale G, Cotrim AP, Bandyopadhyay BC, Riddle K, Mooney D, Kok MR, Chiorini JA, Baum BJ.

Tissue Eng. 2006 Oct;12(10):2939-48.

19.

NOD mouse model for Sjögren's syndrome: lack of longitudinal stability.

Lodde BM, Mineshiba F, Kok MR, Wang J, Zheng C, Schmidt M, Cotrim AP, Kriete M, Tak PP, Baum BJ.

Oral Dis. 2006 Nov;12(6):566-72.

PMID:
17054769
20.

Toxicity and biodistribution of a first-generation recombinant adenoviral vector, in the presence of hydroxychloroquine, following retroductal delivery to a single rat submandibular gland.

Zheng C, Voutetakis A, Kok MR, Goldsmith CM, Smith GB, Elmore S, Nyska A, Vallant M, Irwin RD, Baum BJ.

Oral Dis. 2006 Mar;12(2):137-44.

PMID:
16476034
21.

Enhanced transduction of mouse salivary glands with AAV5-based vectors.

Katano H, Kok MR, Cotrim AP, Yamano S, Schmidt M, Afione S, Baum BJ, Chiorini JA.

Gene Ther. 2006 Apr;13(7):594-601.

PMID:
16341060
22.

Serum lipid levels in Sjögren's syndrome.

Lodde BM, Sankar V, Kok MR, Leakan RA, Tak PP, Pillemer SR.

Rheumatology (Oxford). 2006 Apr;45(4):481-4. Epub 2005 Nov 22.

PMID:
16303821
23.

Adult heart block is associated with disease activity in primary Sjögren's syndrome.

Lodde BM, Sankar V, Kok MR, Leakan RA, Tak PP, Pillemer SR.

Scand J Rheumatol. 2005 Sep-Oct;34(5):383-6.

PMID:
16234186
24.

Salivary glands as a potential gene transfer target for gene therapeutics of some monogenetic endocrine disorders.

Voutetakis A, Bossis I, Kok MR, Zhang W, Wang J, Cotrim AP, Zheng C, Chiorini JA, Nieman LK, Baum BJ.

J Endocrinol. 2005 Jun;185(3):363-72.

PMID:
15930162
25.

Primary culture of polarized human salivary epithelial cells for use in developing an artificial salivary gland.

Tran SD, Wang J, Bandyopadhyay BC, Redman RS, Dutra A, Pak E, Swaim WD, Gerstenhaber JA, Bryant JM, Zheng C, Goldsmith CM, Kok MR, Wellner RB, Baum BJ.

Tissue Eng. 2005 Jan-Feb;11(1-2):172-81.

PMID:
15738672
26.

Immune responses following salivary gland administration of recombinant adeno-associated virus serotype 2 vectors.

Kok MR, Voutetakis A, Yamano S, Wang J, Cotrim A, Katano H, Bossis I, Chiorini JA, Tran SD, Tak PP, Baum BJ.

J Gene Med. 2005 Apr;7(4):432-41.

PMID:
15515118
27.

Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjögren's syndrome.

Pillemer SR, Brennan MT, Sankar V, Leakan RA, Smith JA, Grisius M, Ligier S, Radfar L, Kok MR, Kingman A, Fox PC.

Arthritis Rheum. 2004 Aug 15;51(4):601-4.

28.

Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial.

Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, Baum BJ, Pillemer SR.

Arthritis Rheum. 2004 Jul;50(7):2240-5.

29.

Reengineered salivary glands are stable endogenous bioreactors for systemic gene therapeutics.

Voutetakis A, Kok MR, Zheng C, Bossis I, Wang J, Cotrim AP, Marracino N, Goldsmith CM, Chiorini JA, Loh YP, Nieman LK, Baum BJ.

Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3053-8. Epub 2004 Feb 20.

30.

Advances in vector-mediated gene transfer.

Baum BJ, Goldsmith CM, Kok MR, Lodde BM, van Mello NM, Voutetakis A, Wang J, Yamano S, Zheng C.

Immunol Lett. 2003 Dec 15;90(2-3):145-9. Review. Erratum in: Immunol Lett. 2004 Feb 15;91(2-3):255.

PMID:
14687716
31.

Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjögren's syndrome.

Kok MR, Yamano S, Lodde BM, Wang J, Couwenhoven RI, Yakar S, Voutetakis A, Leroith D, Schmidt M, Afione S, Pillemer SR, Tsutsui MT, Tak PP, Chiorini JA, Baum BJ.

Hum Gene Ther. 2003 Nov 20;14(17):1605-18.

PMID:
14633403
32.

Use of localised gene transfer to develop new treatment strategies for the salivary component of Sjögren's syndrome.

Kok MR, Baum BJ, Tak PP, Pillemer SR.

Ann Rheum Dis. 2003 Nov;62(11):1038-46. Review.

33.

Neural network-based screening (NNS) in cervical cytology: no need for the light microscope?

Kok MR, van Der Schouw YT, Boon ME, Grobbee DE, Kok LP, Schreiner-Kok PG, van der Graaf Y, Doornewaard H, van den Tweel JG.

Diagn Cytopathol. 2001 Jun;24(6):426-34.

PMID:
11391826
34.

Less medical intervention after sharp demarcation of Grade 1-2 cervical intraepithelial neoplasia smears by neural network screening.

Kok MR, Boon ME, Schreiner-Kok PG, Hermans J, Grobbee DE, Kok LP.

Cancer. 2001 Jun 25;93(3):173-8.

PMID:
11391604
36.

Potentially difficult smears of women with squamous cell carcinoma pose fewer problems when PAPNET is used for primary screening.

Kok MR, Schreiner-Kok PG, Van Der Veen G, Boon ME.

Cytopathology. 1999 Oct;10(5):324-34.

PMID:
10588351
37.

New paradigm for ASCUS diagnosis using neural networks.

Kok MR, Habers MA, Schreiner-Kok PG, Boon ME.

Diagn Cytopathol. 1998 Nov;19(5):361-6.

PMID:
9812231
38.

[Possible effectiveness of mass screening of the population for cervical cancer].

Kok MR, Boon ME.

Ned Tijdschr Geneeskd. 1997 May 17;141(20):1015. Dutch. No abstract available.

PMID:
9340547
40.

The click-evoked oto-acoustic emission, c-EOAE, in preterm-born infants in the post conceptional age range between 30 and 68 weeks.

van Zanten BG, Kok MR, Brocaar MP, Sauer PJ.

Int J Pediatr Otorhinolaryngol. 1995 Jun;32 Suppl:S187-97.

PMID:
7665290
41.

Click-evoked oto-acoustic emissions in very-low-birth-weight infants: a cross-sectional data analysis.

Kok MR, van Zanten GA, Brocaar MP, Jongejan HT.

Audiology. 1994 May-Jun;33(3):152-64.

PMID:
8042936
42.

Aspects of spontaneous otoacoustic emissions in healthy newborns.

Kok MR, van Zanten GA, Brocaar MP.

Hear Res. 1993 Sep;69(1-2):115-23.

PMID:
8226331
43.

Click-evoked oto-acoustic emissions in 1036 ears of healthy newborns.

Kok MR, van Zanten GA, Brocaar MP, Wallenburg HC.

Audiology. 1993 Jul-Aug;32(4):213-24.

PMID:
8343078
44.

Growth of evoked otoacoustic emissions during the first days postpartum. A preliminary report.

Kok MR, van Zanten GA, Brocaar MP.

Audiology. 1992;31(3):140-9.

PMID:
1642565

Supplemental Content

Support Center